AGIO - NASDAQ

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

AGIO·NASDAQ

$27.68

-1.1%
HealthcareBiotechnology

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.65B
EPS-7.1200
P/E Ratio-3.89
Earnings Date07/30/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. Earnings Call Transcripts

AGIO · NASDAQ

Related Guides

Blog Categories

Continue your AGIO research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.